The role of PI3 kinase inhibition in various settings in metastatic breast cancer and a payer perspective on differentiating breast cancer at various stages of disease progression.
Testing patients who have received CDK4/6 inhibitors in metastatic breast cancer (MBC) as well as testing patients with ctDNA upon disease progression with a single gene test versus NGS.
March 30th 2021, 3:00pm
The Pfizer and Moderna COVID-19 vaccines were shown to be 90% effective in preventing infection in a real-world setting; Biden administration urges states to pause reopening plans amid signs of COVID-19 surge; a lawsuit seeks to end the requirement that preventive services be provided free of charge to Americans.
March 17th 2021, 2:24pm
The FDA issues updated guidance on the emergency use authorization (EUA) process for COVID-19 screening tools; Eli Lilly releases patient-reported outcome results for Verzenio (abemaciclib) in breast cancer; COVID-19 vaccines possibly improve long-haul symptoms among patients.
February 15th 2021, 8:00pm
The study, presented at the 2020 San Antonio Breast Cancer Symposium, also found that time to first treatment dropped during this period of the coronavirus disease 2019 (COVID-19) pandemic.
February 8th 2021, 5:00pm
A targeted cue-to-action campaign of outreach, education, and incentive can improve uptake of screening mammography.
January 19th 2021, 10:24pm
Severe mental illnesses that precede a breast cancer diagnosis may increase the risk of both all-cause and cancer-specific mortality among women with Medicaid coverage.
January 13th 2021, 2:00pm
Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera, said that attention on finding biomarkers for metastatic reoccurrence needs to be directed at women with a high risk of this happening.
January 11th 2021, 9:20pm
A more aggressive tumor microenvironment may be to blame for the exaggerated inflammatory response more often seen in Black women with breast cancer compared with White women.
January 9th 2021, 2:00pm
Changes in circulating tumor DNA (ctDNA) are indicative of treatment response in early-stage breast cancer, pointed out Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
January 4th 2021, 9:02pm
An abstract from last month’s San Antonio Breast Cancer Symposium identifies factors linked with longer-term controlled substance use after treatment of breast cancer with mastectomy plus breast reconstruction in women receiving opioids, benzodiazepines, and other sedative/hypnotics.
January 1st 2021, 2:00pm
Through neoadjuvant chemotherapy we can downstage tumors, assess drug efficacy, and better segregate women by prognosis status for adjuvant treatment, explained Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
.jpg?w=200&fit=crop&auto=format)
